Dosage Forms & Drug Delivery Systems – Page 45

Post-Approval Change Failure for innovative delivery systems: risk assessment and validation impact analysis

Identifying the early signals of a post-approval change failure is crucial. Symptoms can manifest through various channels, including:Click to read the full article.

Microbial Limits Failure at accelerated stability: GMP documentation for FDA/EMA/MHRA review

Identifying symptoms and signals early on is essential for initiating an appropriate investigation. Common indicators of microbial limits failures during stability testing may include:Click to read the full article.

Method Transfer Failure during PAI readiness: control strategy build-out for inspections

Observation of symptoms or signals is the first step in identifying potential method transfer failures. Symptoms may range from out-of-specification (OOS) results to significant deviations in analytical performance. Recognizing these…

Design Space Missing for long-acting injectables: risk assessment and validation impact analysis

The initial indicators that may suggest a problem with missing design space for long-acting injectables can manifest in various ways:Click to read the full article.

Fill Volume Variability during line setup: investigation steps with CAPA evidence

Symptoms of fill volume variability can manifest at various stages of the manufacturing process and should be closely monitored. Key indicators include:Click to read the full article.

Design Space Missing during PAI readiness: control strategy build-out for inspections

Identifying early signals is critical for detecting issues related to missing design space during PAI readiness. Typical symptoms include:Click to read the full article.

Method Transfer Failure during PAI readiness: decision tree for lab vs manufacturing root cause

Identifying early warning signs is crucial in addressing method transfer failures. Symptoms that may indicate a method transfer issue include:Click to read the full article.

Design Space Missing during PAI readiness: how to document for FDA/EMA/MHRA review

Identifying symptoms of a missing Design Space often begins with observations and reports from production or quality control departments. Common signals include:Click to read the full article.

Sedimentation Oos at accelerated stability: sanitation, water, and EM checks

Identifying sedimentation OOS during stability testing often begins with observable symptoms. Some of the primary signals include:Click to read the full article.

Ivivc Mismatch after formulation change: regulatory-ready investigation and CAPA plan

When an IVIVC mismatch occurs following a formulation change, several signals may alert manufacturing and quality control teams. Common symptoms include:Click to read the full article.

Control Strategy Weakness for innovative delivery systems: risk assessment and validation impact analysis

Recognizing symptoms or signals indicative of a control strategy weakness is the first step in initiating an investigation. In pharmaceutical manufacturing, these can manifest as:Click to read the full article.

Fill Volume Variability in ear drop manufacturing: packaging integrity and stability justification

Understanding the early signals of fill volume variability is crucial for initiating a timely and effective investigation. Symptoms can manifest in various ways:Click to read the full article.